Fatty Liver

#ICFL2022 gathers professionals in Hepatology, Gastroenterology, Diabetology, Nutrition, Radiology, and Cardiology | 28-30 April, Vienna

[Fatty Liver @FattyLiverConf]

📰"The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand"
➡️Read more: https://t.co/IPj7yWAw7W
#ICFL2022 #fattyliver #NAFLD #NASH #livertwitter

[Fatty Liver @FattyLiverConf]

🔙Only two weeks left and the #ICFL2022 virtual platform will close!
🤩Start catching up and watch now➡️ https://t.co/QrUt8PVsmM
#fattyliver #livertwitter #liverdisease #NASH #NAFLD

[Fatty Liver @FattyLiverConf]

🤩You can still enjoy the outstanding scientific content from #ICFL2022!

💻The virtual platform is open until 30 July 2022, giving you 1 more month to rewatch the lectures you found most interesting!
➡️Watch here➡️ https://t.co/QrUt8PDRve #fattyiver #NASH #NAFLD #obesity

[Fatty Liver @FattyLiverConf]

💻Remember all #ICFL2022 sessions, including those that were streamed live, are available on-demand to registered participants until 30 July.
➡️ Still not registered? Click here➡️ https://t.co/QrUt8PDRve
#NASH #NAFLD #fattyliverdisease #liverhealth #fattyliver #livertwitter

[Fatty Liver @FattyLiverConf]

🤩We are glad that so many of you had the chance to attend the amazing #ICFL2022!
➡️The platform will be available until 30 July for all registered participants: https://t.co/OLmh8ZvNGH
➡️If you did not join us in April, the registration is still open: https://t.co/cseXjKwIGx

[Perspectum @PerspectumGroup]

Thank you Professor Rakhi Maiwall for sharing your work and highlighting the strength of your results toward understanding links between PDFF and COVID-19. #ICFL2022. Read more about the paper Dr. Maiwall referenced here: https://t.co/nNMvKAyQUC #ICFL2022

[Jonathan G. Stine, MD MSc, FACP @JonathanStineMD]

🔥⬆️ to learn from this international who's who of #NALFD experts during day #2 of #ICFL2022 @LiverSaver @QAnstee @schattenbergJ and co!

[Fatty Liver @FattyLiverConf]

🤩#ICFL2022 in numbers & photos!

A month has passed since we met at the 3rd International Conference on Fatty Liver. It was an amazing experience to have been together in the beautiful city of Vienna and online!
➡️Take a look at our Photo Gallery➡️ https://t.co/K7ndFtChIf

[Fatty Liver @FattyLiverConf]

💚 At #ICFL2022 we discussed the latest in #FattyLiverDisease, exchanged knowledge and experiences, and had fun.
🙋‍♂️Don't miss out! It is never too late to start learning and save lives ➡️
https://t.co/M0YnFDIDHw
#fattyliverdisease #livertwitter #liverhealth #NASH #NAFLD

[Scott Isaacs @scottisaacsmd]

Identify patients at high-risk for #NAFLD and use the FIB-4 index for fibrosis risk stratification. For indeterminate risk, use elastography or serum biomarkers as a second #NIT. @TheAACE @AASLDtweets #livertwitter #endotwitter

[Fatty Liver @FattyLiverConf]

Thank you for being part of #ICFL2022!

🤩Don’t miss your chance to hear the latest updates in #fattyliver from world-renowned speakers. All #ICFL2022 sessions are available on-demand to registered participants until July 30, 2022.
➡️Still not registered? https://t.co/cseXjKwIGx

[Amreen Dinani @AmreenDinani]

What a great conference #ICFL2022 and fortunate to be able to attend in person and share our real world experience using FAST score to detect fibrotic NASH. We have an uphill battle but confident we'll get there.

[PanNASH Initiative @PanNASH_Init]

Great presentation by @FrancqueSven on #PPARs in #NASH during #ICFL2022. They are are "key" in many ways: regulators, therapeutic tools to tackle NASH. @Dufourjeanfran1 @JVLazarus @schattenbergJ @VladRatziu @FaiezZANNAD

[Jonathan G. Stine, MD MSc, FACP @JonathanStineMD]

1/3- I've been thinking more about what #ArunSanyal said during #ICFL2022 about the lack of behavioral research in #NAFLD. In order for lifestyle change with #diet and #exercise to be widely and successfully adopted, we need to better understand human behavior @FattyLiverConf

[PanNASH Initiative @PanNASH_Init]

For completing a healthy lifestyle & #diabetes control, many anti-NASH treatments are in development. For #NASH patients, the first opportunity is entering into a
clinical study

#PanNASH #NAFLD #LiverTwitter @EASLnews @FattyLiverConf @EASLedu @AlkhouriNaim

[Juan Turnes @jturnesv]

The last week of April ends with #livertwitter at the top

@rabataller @jturnesv @ebtapper @LancetGastroHep @AEEHLiver @HepatomaRes @UEGJournal @LiverFellow @FattyLiverConf @NnekaUfereMD

[Fatty Liver @FattyLiverConf]

Thank you for being part of #ICFL2022!🤩

It truly was an amazing experience!
Remember that the sessions will be available to view on demand for 3 months after the Conference!
#hybridevent #fattyliver #livertwitter

[Marina García Macia @Juanaloca2002]

Closing remarks of a great meeting #ICFL2022 @FattyLiverConf see you all soon !!

[Marina García Macia @Juanaloca2002]

Panel discussion now...#ICFL2022 @FattyLiverConf

[Marina García Macia @Juanaloca2002]

Last talk of the Session 6 #ICFL2022 by Johny Amer from @Hadassah about the antagonizing NTCP on NK cells to kill stellate cells in NAFLD patients @FattyLiverConf